Accrued Expenses and Restructuring Reserve (Details) - USD ($)	6 Months Ended
	Jun. 30, 2019		Dec. 31, 2018
Accrued Expenses and Other Liabilities [Abstract]
Accrued research and development costs	$ 91,229		$ 71,329
Accrued professional fees	242,732		421,617
Accrued compensation	304,225		54,269
Accrued other	0		46,674
Accrued rent	0		8,000
Total	638,186		601,889
Restructuring Reserve [Abstract]
Restructuring reserve	1,283,875	[1]	0
Total	1,283,875		$ 0
Restructuring expense paid	$ 786,396

[1] Restructuring reserve relates to the severance costs incurred by Edge Therapeutics prior to the merger transaction and assumed by the Company as part of the purchase accounting, but not yet paid. The severance costs continue through September 2020. For the six months ended June 30, 2019, the Company paid $786,396 of restructuring expense which was previously recorded on Edge Therapeutics financials.